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Abstract
Background: The aim was to describe the prevalence and characteristics of difficult to manage dyskinesia associated with subthalamic nucleus (STN) deep brain
stimulation (DBS). A small subset of STN DBS patients experience troublesome dyskinesia despite optimal programming and medication adjustments. This group of
patients has been referred to by some practitioners as brittle STN DBS-induced dyskinesia, drawing on comparisons with brittle diabetics experiencing severe blood
sugar regulation issues and on a single description by McLellan in 1982. We sought to describe, and also to investigate how often the ‘‘brittle’’ phenomenon occurs
in a relatively large DBS practice.
Methods: An Institutional Review Board-approved patient database was reviewed, and all STN and globus pallidus internus (GPi) DBS patients who had surgery
at the University of Florida from July 2002 to July 2012 were extracted for analysis.
Results: There were 179 total STN DBS patients and, of those, four STN DBS (2.2%) cases were identified as having dyskinesia that could not be managed
without the induction of an ‘‘off state,’’ or by the precipitation of a severe dyskinesia despite vigorous stimulation and medication adjustments. Of 75 GPi DBS cases
reviewed, none (0%) was identified as having brittle dyskinesia. One STN DBS patient was successfully rescued by bilateral GPi DBS.
Discussion: Understanding the potential risk factors for postoperative troublesome and brittle dyskinesia may have an impact on the initial surgical target selection
(STN vs. GPI) in DBS therapy. Rescue GPi DBS therapy may be a viable treatment option, though more cases will be required to verify this observation.
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Introduction
Dopamine-induced dyskinesia (DID) is a common complication of
Parkinson’s disease (PD) and also of pharmacological replacement
therapy.1–3 Typical management of DID includes changing dosages
and dosage intervals.4 The treatment may also involve alterations in
multiple different dopaminergic medications.5,6 Refractory on–off
fluctuations and dyskinesia despite multiple medication adjustments
commonly results in referral for consideration of deep brain
stimulation (DBS).5 Subthalamic nucleus (STN) and globus pallidus
internus (GPi) DBS have both been recently documented to be
reasonable treatment approaches for addressing on–off fluctuations
and for addressing treatment of intractable dyskinesia.6,7 There are,
however, a small subset of patients in whom we have observed that
management utilizing STN DBS has resulted in either troublesome
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dyskinesia or, alternatively, when changing the DBS setting,
unacceptable ‘‘off time periods.’’ We refer to this group of patients
as ‘‘brittle’’ STN DBS-associated dyskinesia, drawing an analogy to a
brittle diabetic whose blood sugars cannot be managed despite
aggressive medical and behavioral therapy. In 1982 McLellan and
Dean8 also employed the term brittle Parkinsonism to describe a
patient who alternated between severe bradykinesia and violent chorea
as a result of her medication regimen. Striking the balance between
medications and stimulation in this patient group may not satisfactorily
address an individual brittle PD patient’s disabling symptoms. We will
review and discuss four such cases. One case was rescued using
bilateral GPi DBS.
Methods
The IRB-approved UF-INFORM patient database was reviewed
and all STN DBS patients operated at the University of Florida from
July 2002 to July 2012 were included. Of 197 total cases, four patients
(2%) were identified with severe and difficult to manage stimulation-
induced dyskinesia. These cases could not be managed without the
induction of an ‘‘off state’’, or alternatively by precipitating a severe
dyskinetic state despite vigorous stimulation and also medication
adjustments. The patients were all evaluated in person at the
University of Florida site and medication and stimulation settings
were aggressively optimized monthly for at least 6 months following
each DBS lead implantation operation.
Of 75 total GPi cases, none was identified with the brittle dyskinesia
phenomenon.
Case 1
A 48 year-old right-handed male with an 8-year history of PD
presented with progressive difficulty walking. He complained of
bradykinesia and this symptom was followed by an intermittent right
hand resting tremor. He was initially treated with ropinirole, and then
with pramipexole, but these therapies were discontinued due to
medication intolerance. He was successfully initiated on a titration of
carbidopa/levodopa, and he reported cessation of all disabling PD
symptoms for 3 years. As his disease duration lengthened, and his
dosages were increased, his dosage intervals decreased, and his medical
management increased in complexity. He developed motor fluctua-
tions, peak dose dyskinesia, and problems sleeping. His optimal
medication regimen was 1–1.5 tablets of 25/100 carbidopa/levodopa
administered every 3 h, along with amantadine 100 mg twice a day,
and rasagiline 1 mg once a day. One 25/100 carbidopa/levodopa
tablet resulted in a short-lasting benefit for less than 1 h, and 1.5
tablets of carbidopa/levodopa resulted in troublesome and disabling
dyskinesia. He reported that his peak dose dyskinesia was more
disabling than his off-medication state symptoms. He underwent
interdisciplinary screening for consideration of DBS.
He underwent bilateral staged STN DBS with a 6-month time lapse
between the implantation of each hemisphere (left then right).
Following left-sided STN DBS, he experienced right upper extremity
and right lower extremity dyskinesia at both the 1 and the 2 contacts
on the DBS lead (Medtronic 3387, Minneapolis, MN). The 1 and 2
DBS lead contacts corresponded to his best therapeutic benefit during
programming sessions. Multiple programming strategies were
employed, including attempts at slow stimulation titrations, and the
use of a more dorsal DBS contact site. The dyskinesia only abated
when the DBS was turned off. Attempts were made to commensurately
decrease carbidopa/levodopa dosage in combination with stimulation
changes, but this worsened his off state, though at low medication
dosages dyskinesia abated (preoperative levodopa equivalent dose was
1,000, postoperative was 720, and post-rescue GPi was 1,220). He
experienced a similar clinical scenario when the right STN DBS was
added. At settings that improved his freezing of gait, he had
bothersome left lower extremity dyskinesia. Many other attempted
settings failed to capture his gait freezing and his off symptoms.
He underwent rescue bilateral staged GPi DBS in a single operative
sitting, and following programming, the dyskinesia completely abated,
and he was able to maintain a smooth on medication state. His
preoperative medications before rescue bilateral GPi placement were
carbidopa/levodopa 25/100, half to one tablet every 3.5–4 h, and
ropinirole XL 8 mg twice a day. At 4 months postoperatively, he had
been completely weaned off the ropinirole XL, and he was taking
carbidopa/levodopa one tablet every 3.5 h. The lead locations for the
active DBS contacts are summarized in Table 1. The Unified
Parkinson’s Disease Rating Scale (UPDRS) pre- and postoperative
scores are summarized in Table 2.
Case 2
A 73-year-old man with a 14-year history of idiopathic PD reported
that his initial symptom was a right hand resting tremor. He developed
bradykinesia, rigidity, and a shuffling gait. Over the course of 5 years
he developed on–off fluctuations and dyskinesia. He responded to
carbidopa/levodopa; however the development of motor fluctuations,
dose failures, and disabling peak dose dyskinesia led to a referral for
DBS therapy. Eleven years following his diagnosis he received a right
STN DBS.
Postoperatively, he had dyskinesia in his left upper extremity and left
lower extremity when he was stimulated at contacts 1, 2, and 3 on his
DBS lead (Medtronic 3387), and with medications off. All of these
DBS contact locations provided therapeutic benefits. He had the
greatest benefits at contacts 1 and 2, but, as the voltages were slowly
increased, he developed severe dyskinesia. Following multiple DBS
programming sessions, he reported persistent and bothersome
dyskinesia. Seven months after his initial left STN DBS surgery, he
received a right STN DBS. Again, stimulation at contacts 1 and 2
resulted in good tremor control, but he had intolerable stimulation-
induced dyskinesia in the left upper and lower extremity even with
medications off. He had persistent dyskinesia even after multiple
programming sessions. Attempts to decrease medication, to slowly
increase his voltage, and to use more dorsal DBS contacts failed to
suppress the dyskinesia. His preoperative levodopa equivalent dose was
475 and postoperative was 400. His postoperative course was
complicated by dopamine dysregulation syndrome (DDS). His
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caregiver reported worsened cravings for levodopa postoperatively;
however, DDS was thought to be possibly present preoperatively. He
was started on valproic acid extended release 250 mg at bedtime, and
he reported resolution of DDS.10
His optimized preoperative medications included carbidopa/
levodopa/entacapone 100 mg every 3 h. His optimized postoperative
medications were carbidopa/levodopa immediate release 25/250, 0.5
of a tablet every 2 h for a total of seven to eight doses, and amantadine
100 mg twice daily. His dyskinesia persisted even off medication, and
when at optimized DBS settings.
Case 3
A 50-year-old right-handed Hispanic man with a 9-year history of
PD was referred to our center for a DBS candidacy evaluation. Right
upper extremity stiffness and slowness were the initial symptoms, and
he was diagnosed with PD. Carbidopa/levodopa was the first
medication attempted, and this medication resulted in significant
clinical improvement in PD symptoms. Two years after his initial
diagnosis, he noticed difficulty with walking, but this improved with
adjustment in his carbidopa/levodopa dosage. Four years after the
diagnosis, he reported having troublesome right upper and lower
extremity resting tremor. Eight years into his disease, he reported a left
upper extremity resting tremor. The dosage of carbidopa/levodopa
was increased numerous times over many years in order to address
symptom worsening, and the emergence of new PD-related symptoms.
Pramipexole was tried and was discontinued due to excessive daytime
somnolence, and due to sleep attacks when driving. He also reported a
5-year history of depression, and he was put on venlafaxine 75 mg
XR. The dose was increased to a total of 225 mg per day. His
depression resolved. He reported motor fluctuations, sudden unpre-
dictable offs, and peak dose dyskinesia that progressively worsened
over 4 years. Amantadine, 100 mg twice a day, was mildly helpful in
controlling dyskinesia.
He received staged bilateral STN DBS (second implant at 6 months)
starting with a left-sided implantation (Medtronic 3387). Tremor and
motor fluctuations improved, but he experienced persistent dyskinesia
that was unrelated to the carbidopa/levodopa dosages (occurred in the
off-medication condition), and the dyskinesia abated when the DBS
was switched off. Preoperative levodopa equivalent dose was 800, and
postoperatively it was 1,050. The optimal stimulation settings where he
derived good tremor control, also evoked severe dyskinesia. Despite
discontinuation of selegiline, and also carbidopa/levodopa dose
reductions, the bothersome dyskinesia persisted. Multiple program-
ming sessions and gradual increases in programming parameters, and
also the use of more dorsal DBS contacts, all resulted in bothersome
dyskinesia.
Case 4
A 75-year-old Caucasian woman with a 12-year history of PD
presented to our center for an evaluation. Right hand resting tremor
was the initial symptom, and she later developed slowness of
movements, stiffness, and decreased dexterity of her right side.
Symptoms were insidious onset and progressive. Over the next few
Table 1. DBS Lead Locations for Active Contacts
Patient DBS Lead y x z
Case 1 Left STN 21.30 212.6 24.35
Right STN 20.40 11.16 20.30
Left GPi 4.28 220.7 21.40
Right GPi 7.45 23.07 21.23
Case 2 Left STN 0.81 212.3 21.48
Right STN 20.23 13.8 20.92
Case 3 Left STN 21.69 211.9 2.83
Right STN 20.20 11.58 1.91
Case 4 Left STN 22.98 212.3 21.27
Right STN 0.13 9.69 23.45
DBS, Deep Brain stimulation; GPi, globus pallidus internus; STN,
subthalamic nucleus.
A summary of the location of the active STN DBS contact(s) with
respect to mid-commissural point in antero-posterior (y), lateral (x),
and axial (z) plane measured in millimeters from a postoperative
computed tomography–magnetic resonance imaging fusion.






medication and on DBS
Postoperative on-
medication and on DBS
Patient 1 45 (43 GPi) 31 (35 GPi) 39 (34 GPi) 25 (29 GPi)
Patient 2 52 40 44 34
Patient 3 46 15 25 14
Patient 4 40 20 N/A N/A
DBS, Deep Brain stimulation; GPi, globus pallidus internus; STN, subthalamic nucleus; UPDRS, Universal Parkinson’s Disease Rating Scale.
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years, she developed difficulty walking, and noticed tremor in her left
hand. Pramipexole was the first medication tried, but was discontinued
due to hallucinations and dyskinesia. When evaluated at our center,
she was on carbidopa/levodopa 25/100 1.5 tablets every 4 h and
ropinirole 1 mg three times a day. Tremors were not fully captured,
and an attempt to increase the dose of carbidopa/levodopa was met
with bothersome peak dose dyskinesia, orthostatic hypotension, and
syncope. She was placed on fludrocortisone 0.1 mg three times a day
and midodrine 10 mg three times a day for orthostatic hypotension,
and her syncope resolved. She was placed on escitalopram 10 mg once
a day for depression and on methylphenidate 10 mg once a day for
daytime sleepiness and fatigue.
She received bilateral STN DBS (Medtronic 3387) starting with a
left-sided implantation (implants staged over 6 months). Her tremors
improved, but she developed bilateral stimulation-induced dyskinesia
(even when off medications). DBS settings that revealed tremor benefit
resulted in troublesome dyskinesia. At DBS settings where she was not
experiencing stimulation dyskinesia, she could not achieve tremor
control. Despite multiple device programming sessions and the use of
dorsal DBS contacts, the stimulation-induced dyskinesia persisted.
There were multiple unsuccessful attempts made to adjust medica-
tions. The preoperative levodopa equivalent dose was 1,200 and the
postoperative dose was 1,000. The lead locations for the active DBS
contacts are summarized in Table 1. The UPDRS pre- and
postoperative scores are summarized in Table 2.
Discussion
An infrequent but nonetheless potential complication of STN DBS
has been difficult to control stimulation-induced dyskinesia. Some DBS
practitioners have clinically dubbed the phenomenon as ‘‘brittle
dyskinesia,’’ drawing a comparison to brittle diabetics. 1 The
emergence of troublesome dyskinesia post-STN DBS has been
challenging; however, rescue GPi DBS has proven effective in one of
our cases, but was not attempted in the other three. There are several
important issues worthy of discussion about the occurrence and
treatment of this phenomenon.
The predictors and risk factors for the occurrence of troublesome
‘‘brittle’’ dyskinesia post bilateral STN DBS remain unknown. It will
be important to draw on larger pooled datasets from multiple expert
DBS centers to ascertain better predictor and more accurate risk factor
information. Young-onset PD (without DBS) has been associated with
the occurrence of ‘‘more’’ dyskinesia in some published studies, though
this issue must be more carefully examined.7,9 Two of the four cases in
this series were below the age of 50 when they developed PD. This
observation raises the possibility that young-onset of PD may play a
role in the genesis of this post-STN DBS brittle dyskinesia; however,
we must consider that our other two cases were elderly.10,11
Interestingly, no cases of brittle dyskinesia were observed in our
patients initially implanted with GPi DBS. Recently there was a paper
from our group that examined a definition for brittle dyskinesia and
risk factors.27 In this report, the brittle response occurred more
commonly in patients with a longer disease duration, longer duration
of levodopa therapy, and in female patients with a low body weight.
Whether these risk factors will be the same as in DBS-induced brittle
dyskinesia remains unknown, and a large multicenter study would be
required to answer this question.
We wondered whether patients with severe dyskinesia preoperatively,
even at relatively low dopaminergic dosages, could be at risk for this
phenomenon; however, our sample size was too small to ascertain this
information. Prior to DBS, all of our cases were observed to tolerate
carbidopa/levodopa 25/100, and all were taking medications every few
hours during wakefulness. One patient had a possible preoperative
dopamine dysregulation syndrome, and none had Impulse Control
Disorders (ICDs). Therefore, the role of medication and of pre-morbid
behavior syndromes remains unknown, but should also be investigated.
Stimulation-induced dyskinesia has been commonly reported as a
side effect of STN DBS.12 In most cases when this phenomenon
occurs, it has been interpreted as a good prognostic sign, indicating
that the optimal lead location has been achieved.13 Further, the
occurrence of stimulation-induced dyskinesia in the operating room
setting has been referenced as a positive predictive sign by DBS
practitioners, though this has never been validated.14,15 No cases of
brittle dyskinesia were reported in the available randomized DBS
studies, though multiple authors from large DBS centers have
communicated verbally to us that they have observed this phenom-
enon.16–19 We suspect the small number of reports may be due to both
a low prevalence, and also under-reporting, though it should be noted
that simple uncomplicated and non-troublesome stimulation-induced
dyskinesia occurs frequently with DBS therapy.12,15
Another possible predictor of stimulation-induced dyskinesia may be
location of the DBS lead’s actively utilized contact. Though
stimulation of the dorsal STN and zona incerta has been reported to
improve parkinsonism, stimulation within the STN itself may provoke
the dyskinesia.20,21 These observations have not been confirmed in a
larger series, and may be subject to great bias. It is however possible
that the current spread into the dorsally adjacent lenticularis fasciculus
and zona incerta exerts an effect similar to that of pallidal stimulation,
and ultimately suppresses dyskinesia.22 This issue remains unresolved.
Fifteen percent of the PD patients who underwent unilateral
subthalamotomy in the large Cuban series developed hemichorea and
hemiballism postoperatively, and more than half required a subse-
quent pallidotomy to effectively control their symptoms.23 All of these
patients were reported to have achieved adequate motor benefits on
long-term follow-up. This observation may at least partially explain
why the GPi target for DBS was successful as a rescue procedure for
dyskinesia suppression in our single case.
Boulet et al.24 reported that in a hemi-parkinsonian rat model high-
frequency STN DBS induced forelimb dyskinesia. These authors also
reported that dyskinesia was aborted by injection of a glutamate
receptor antagonist into the substantia nigra. The experiment suggests
that glutamate neurotransmitter release may underpin stimulation-
induced dyskinesia; however, the exact mechanisms remain unknown.
Though this paper was limited by a small sample size, the
implications of this phenomenon are important as they may potentially
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impact the initial surgical target site selection (STN vs. GPI) for DBS
therapy. It is important to consider that every preoperative PD patient
likely possesses a different dyskinesia threshold, and this threshold can
be difficult to account for especially in small studies. Additionally,
occasionally small strokes and hemorrhages can lead to similar findings
as reported in this series; however, these phenomena were not present
in our cases. Nutt and colleagues25,26 also observed that frequently the
threshold to improve PD symptoms with medications is the same or
close to the threshold for dyskinesia. Our correspondence with
multiple large DBS centers supports the data from our center,
suggesting that this phenomenon occurs in a small handful of DBS
patients, and that it seems to occur with the STN target. GPi DBS
proved effective in one of our patients for suppressing dyskinesia, and
therefore rescue GPi DBS maybe a viable treatment option in cases
where the dyskinesia is bothersome and disabling, though more cases
will be required to verify the observation. A large multicenter effort will
likely be needed to better understand the brittle phenomenon and to
define the most appropriate brain target for treatment. Rescue GPi
DBS was only attempted on case 1 in our series. Case 2 preferred
programming and medication adjustments vs. another operation. Case
3 was a poor reoperation candidate (age and frailty) and passed away
from an unrelated cause. Case 4 was lost to follow-up. It remains
unknown if GPi DBS should be preoperatively chosen as the target for
patients with very severe and disabling dyskinesia, and when rescue
GPi lead(s) should be offered.
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